Clinical trial
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the…
NCT00218205 · Department of Veterans Affairs, New Jersey, U.S. Fed · Unknown status
Key facts
| NCT number | NCT00218205 |
|---|---|
| Title | A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer |
| Official title | A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC) |
| Lead sponsor | Department of Veterans Affairs, New Jersey, U.S. Fed |
| Collaborators | Pfizer Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Epirubicin, Estramustine Phosphate, Celecoxib |
| Enrollment | 28 |
| Start date | Jul 1, 2002 |
| Completion | Jun 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 22, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: